{"created":"2023-05-15T14:34:43.430788+00:00","id":44880,"links":{},"metadata":{"_buckets":{"deposit":"76ee4873-51e2-432e-9103-f96ce1bda919"},"_deposit":{"created_by":1,"id":"44880","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"44880"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00044880","sets":["1"]},"author_link":["445755","445745","445747","445751","445750","445752","445754","445746","445753","445748","445749"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"11","bibliographicPageEnd":"1579","bibliographicPageStart":"1575","bibliographicVolumeNumber":"94","bibliographic_titles":[{"bibliographic_title":"British Journal of Cancer"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. S-1 was given orally (30 mg m(-2)) b.i.d. for 14 consecutive days and gemcitabine (1000 mg m(-2)) was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was eight (range 1-20). Grade 3-4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%), anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33-65). Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate.","subitem_description_type":"Abstract"}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0007-0920","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nakamura, Kazutaka"}],"nameIdentifiers":[{"nameIdentifier":"445745","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamaguti, Taketo"}],"nameIdentifiers":[{"nameIdentifier":"445746","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ishihara, Takeshi"}],"nameIdentifiers":[{"nameIdentifier":"445747","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kobayashi, Akitoshi"}],"nameIdentifiers":[{"nameIdentifier":"445748","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tadenuma, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"445749","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sudo, Kentaro"}],"nameIdentifiers":[{"nameIdentifier":"445750","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Katou, Hirotoshi"}],"nameIdentifiers":[{"nameIdentifier":"445751","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saisho, Hiromitsu"}],"nameIdentifiers":[{"nameIdentifier":"445752","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山口 武人","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"445753","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 博敏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"445754","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"税所 宏光","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"445755","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2007-06-15"},"publish_date":"2007-06-15","publish_status":"0","recid":"44880","relation_version_is_last":true,"title":["Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T00:10:15.592696+00:00"}